Chicago Multidisciplinary Symposium in Thoracic Oncology | Conference

Expert Predicts the Future of Immune Therapies for Lung Cancer

November 1st 2014

Roy S. Herbst, MD, PhD, presented a top 10 list on immunotherapy in non-small cell lung cancer at the 2014 Multidisciplinary Symposium in Thoracic Oncology.

Dr. Patel on the Benefits of a Multidisciplinary Approach for Patients With Stage III Lung Cancer

November 1st 2014

Jyoti D. Patel, MD, thoracic oncologist, Northwestern University Feinberg School of Medicine, discusses the benefits of multidisciplinary approach for the treatment of patients with stage III disease.

Dr. Spigel Discusses Results from a Phase III Study Exploring Eribulin in NSCLC

November 1st 2014

David Spigel, MD, director of Lung Cancer Research at the Sarah Cannon Research Institute, discusses results from a phase III study exploring eribulin for the treatment of patients with non-small cell lung cancer.

Nivolumab Plus Chemotherapy Shows Similar Efficacy to Nivolumab Monotherapy in NSCLC

November 1st 2014

Nivolumab combined with platinum-based doublet chemotherapy achieved a manageable safety profile with clinical efficacy that was similar to single-agent nivolumab in patients with advanced NSCLC.

Expert Advises on Managing Side Effects of Targeted Lung Cancer Therapies

November 1st 2014

Jyoti D. Patel, MD, provides insight into managing the toxicities associated with molecular therapies used to treat patients with lung cancers.

Phase II Study Shows Promising Efficacy for Nivolumab in Advanced NSCLC

October 31st 2014

The PD-1 immune checkpoint inhibitor nivolumab achieved an ORR of 15% with a median duration of response that was not yet reached at a median 11-month follow-up for patients with advanced, refractory NSCLC.

Afatinib Extends OS by Approximately 1 Year in Subgroup of NSCLC

October 31st 2014

First-line afatinib (Gilotrif) improved overall survival (OS) by about 1 year in patients with advanced non–small cell lung cancer (NSCLC) whose tumors harbor EGFR exon 19 deletions according to results from the LUX-Lung 3 and the LUX-Lung 6 phase III randomized trials.

Dr. Govindan on the Potential for Alectinib

October 31st 2014

Ramaswamy Govindan, MD, Director, Thoracic Oncology, Co-Director, Section of Medical Oncology, Washington University School of Medicine, Siteman Cancer Center, discusses the potential for the ALK inhibitor alectinib.

Post-Operative Radiation Therapy Improves Overall Survival in NSCLC Patients

October 31st 2014

Patients with NSCLC who received postoperative radiation therapy lived 4 months longer on average than patients who did not receive radiation but who had the same disease site, tumor histology, and treatment criteria, according to a large retrospective study.

Dr. Camidge on Inhibiting Initial Activating EGFR Mutations and the T790M Resistance Mutation

October 31st 2014

D. Ross Camidge, MD, PhD, discusses CO-1686 (rociletinib) and AZD9291, two agents that inhibit initial activating EGFR mutations and the T790M resistance mutation.

Molecular Profiling Reveals Potential Targets in SCLC, Lung NETs

October 30th 2014

Molecular profiling has revealed several tumor markers that could be utilized as therapeutic targets for patients with small cell lung cancer (SCLC) or lung neuroendocrine tumors (NETs).

PCP Knowledge Gap Could Affect Lung Cancer Screening Implementation

October 30th 2014

A new study suggests a knowledge gap in Primary Care Providers' familiarity with screening guidelines could also be a barrier to successful implementation.

Dr. Sequist Discusses the OS Analysis of LUX-Lung 3 and LUX-Lung 6

October 30th 2014

Lecia V. Sequist, MD, medical oncologist, associate professor, Massachusetts General Hospital, Harvard Medical School, discusses the overall survival analysis of the LUX-Lung 3 and LUX-Lung 6 trials.

Reducing Lung Biopsies May Cut Costs, Improve Patient Outcomes

October 30th 2014

Biopsies were found to be the most costly tool used in lung cancer diagnosis, and may be performed too frequently based on negative test results and adverse events.

Dr. Gandara Discusses the Future of Clinical Trial Designs

October 30th 2014

David R. Gandara, MD, from UC Davis Comprehensive Cancer Center, discusses the future of clinical trial designs.

Dr. Spigel Discusses the Evolving NSCLC Treatment Landscape

September 14th 2012

Dr. David Spigel, from the Sarah Cannon Research Institute, discusses the rapidly evolving non-small cell lung cancer treatment landscape.

Dr. Reckamp Evaluates the Predictive Efficacy of VeriStrat

September 14th 2012

Dr. Karen Reckamp, from City of Hope, evaluates the predictive efficacy of the pretreatment serum test VeriStrat for non-small cell lung cancer.

Targeted Therapy Combination Slows NSCLC

September 14th 2012

Patients with refractory non-small cell lung cancer had a statistically significant improvement in PFS when treated with targeted therapy duo versus a single agent.

Mutation Confers Anti-EGFR Resistance

September 14th 2012

A common mutation in NSCLC confers resistance to tyrosine kinase inhibitors and worsens survival, creating a need for an alternative approach to treating the subgroup of patients with the mutation.

Hint of Survival Benefit in NSCLC With Bavituximab Plus Docetaxel

September 13th 2012

Patients with advanced non-small cell lung cancer lived twice as long when they received an indirect angiogenesis inhibitor plus docetaxel instead of docetaxel alone.

NEXT PAGE
PREVIOUS PAGE